导航α-同核素聚合抑制:方法,机制和分子标
Maksym Galkin1, Anastasiia Priss1, Yevhenii Kyriukha2
1Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
概括
研究人员审查了α-synuclein (α-synuclein) 纤维细胞形成的抑制剂,这是帕金森病的一个关键过程. 了解这些抑制剂.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种无法治愈的,与年龄相关的神经退行性疾病.
- 患PD的一个标志是神经元蛋白α-synuclein (α-synuclein) 聚合成粉样纤维.
- 抑制α-synuclein聚合是PD的一种有前途的治疗策略.
研究的目的:
- 提供针对α-synuclein纤维化的抑制剂的全面概述.
- 批判性地分析各种抑制剂的作用机制和特异性.
- 为了比较针对各种α-synuclein物种的不同策略.
主要方法:
- 关于α-synuclein纤维化的小分子,和蛋白质抑制剂的文献综述.
- 抑制剂特异性和作用机制的分析,包括多氧化和α-synuclein交叉链接.
- 针对单质,寡质和纤维状α-synuclein的方法的比较.
主要成果:
- 报道了各种类型的抑制剂 (小分子,,蛋白质).
- 抑制剂的有效性与特异性和诸如多氧化和交叉链接等机制有关.
- 针对不同α-synuclein物种的策略具有明显的优点和缺点.
结论:
- 为帕金森病开发改变疾病的治疗方法,需要对α-synuclein聚合抑制剂有深入的了解.
- 对抑制机制和特异性的批判性分析对于治疗开发至关重要.
- 需要进一步的研究来优化向α-synuclein物种和测试抑制剂疗效的策略.
更多相关视频
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.6K
09:16Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
7.6K
相关概念视频
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
